Lebanon VA Medical Center Surgical Clinic 1700 S Lincoln Ave, Lebanon, PA 17042 7172726621 (phone), 7172286118 (fax)
Education:
Medical School Sun Yat Sen Univ of Med Sci, Guangzhou, China (242 21 Pr 1/71) Graduated: 1982
Procedures:
Bone Marrow Biopsy Chemotherapy
Conditions:
Anemia Iron Deficiency Anemia Non-Hodgkin's Lymphoma Breast Neoplasm, Malignant Hemolytic Anemia
Languages:
English
Description:
Dr. Liu graduated from the Sun Yat Sen Univ of Med Sci, Guangzhou, China (242 21 Pr 1/71) in 1982. He works in Lebanon, PA and specializes in Hematology/Oncology and Internal Medicine. Dr. Liu is affiliated with Lebanon VA Medical Center.
Garfield Health Center 210 N Garfield Ave STE 203, Monterey Park, CA 91754 6263077397 (phone), 6263071807 (fax)
Education:
Medical School Hunan Med Univ, Changsha City, Hunan, China Graduated: 1985
Languages:
Chinese English Spanish Vietnamese
Description:
Dr. Liu graduated from the Hunan Med Univ, Changsha City, Hunan, China in 1985. She works in Monterey Park, CA and specializes in Internal Medicine. Dr. Liu is affiliated with Garfield Medical Center and Pacific Alliance Medical Center.
Sep 2013 to 2000 Legal InternWealth Strategies Journal
Aug 2013 to 2000 Associate EditorU.S. Securities and Exchange Commission Washington, DC Jan 2013 to May 2013 Legal ExternSiemens Ltd. China, Legal Department
Apr 2012 to Jul 2012 Assistant CounselIntermediate People's Court of Zhangzhou City
Aug 2011 to Aug 2011 Chief Judge's AssistantYi Lian Law Aid Center
Mar 2011 to Jun 2011 Volunteer CounselConcord & Partners Law Firm
Jun 2010 to Jul 2010 Legal Intern
Education:
Georgetown University Law Center Washington, DC 2013 Master of LawsTsinghua University 2008 to 2012 Bachelor of Laws
- Bethesda MD, US - North Carolina NC, US Kyle Ryan BRIMACOMBE - Bethesda MD, US Mindy Irene Emily DAVIS - Rockville MD, US Yuhong FANG - Rockville MD, US Matthew HALL - Rockville MD, US Ajit JADHAV - Chantilly VA, US Li LIU - Germantown MD, US Natalia MARTINEZ - Rockville MD, US Andrew Louis MCIVER - Durham NC, US Rajan PRAGANI - Gaithersburg MD, US Jason Matthew ROHDE - Poolesville MD, US Anton SIMEONOV - Bethesda MD, US Wei ZHAO - Rockville MD, US Min SHEN - Boyds MD, US
International Classification:
C07D 417/14 C07D 487/08 A61K 31/4995 A61K 31/496
Abstract:
A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; Rand Rare each independently a halogen, CN, CF, CHF, CHF, a C-C10alkyl group, a C1-Calkoxy group, a di(C-Calkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.
- Bethesda MD, US - Chapel Hill NC, US Rajan Pragani - Gaithersburg MD, US LI Liu - Germantown MD, US Mindy Irene Emily Davis - Rockville MD, US Kyle Ryan Brimacombe - Bethesda MD, US Min Shen - Boyds MD, US Anton Simeonov - Bethesda MD, US Daniel Jason Urban - Rockville MD, US Ajit Jadhav - Chantilly VA, US Xiaodong Wang - Chapel Hill NC, US Andrew Louis McIver - Durham NC, US
Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X, X, Rand Rare disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.
Galactokinase Inhibitors For The Treatment And Prevention Of Associated Diseases And Disorders
- Bethesda MD, US - Salt Lake City UT, US Li Liu - Germantown MD, US Cordelle D. Tanega - Rockville MD, US Min Shen - Boyds MD, US Kent Lai - Salt Lake City UT, US Manshu Tang - Salt Lake City UT, US Douglas S. Auld - Beverly MA, US
Disclosed are inhibitors of human galactokinase of formula (I) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I).
Chimeric Antigen Receptors To Control Hiv Infection
- Bethesda MD, US Li Liu - Bethesda MD, US Bhavik Patel - Bethesda MD, US Steven A. Rosenberg - Potomac MD, US Richard A. Morgan - Cambridge MA, US Mustafa H. Ghanem - Brooklyn NY, US Barna Dey - Germantown MD, US
Assignee:
Health and Human Services - Bethesda MD
International Classification:
C07K 14/73 C07K 16/10
Abstract:
The present disclosure is directed to novel multispecific chimeric antigen receptor (CAR) proteins and DNA sequences encoding these proteins. The CARs comprise at least two extracellular domains fused, via a transmembrane domain to a cytoplasmic signaling domain comprising two signaling domains. The disclosure further relates to nucleic acids encoding the novel CARs, to host cells expressing the novel CARs, and to methods of using the CARs to co-stimulate effector functions in the cells and for using cells expressing the receptors for treatment of disease and viral infections. The disclosure also relates to methods of generating a recombinant T cell with reduced susceptibility to HIV infection.
Galactokinase Inhibitors For The Treatment And Prevention Of Associated Diseases And Disorders
- BETHESDA MD, US - SALT LAKE CITY UT, US Li Liu - Germantown MD, US Cordelle D. Tanega - Rockville MD, US Min Shen - Boyds MD, US Kent Lai - Salt Lake City UT, US Manshu Tang - Salt Lake City UT, US Douglas S. Auld - Beverly MA, US
International Classification:
A61K 31/517 A61K 31/506 A61K 31/527
Abstract:
Disclosed are inhibitors of human galactokinase of formula (1) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I).
Galactokinase Inhibitors For The Treatment And Prevention Of Associated Diseases And Disorders
Matthew B. Boxer - New Market MD, US Martin J. Walsh - Carmel IN, US Li Liu - Germantown MD, US Cordelle D. Tanega - Virginia Beach VA, US Min Shen - Boyds MD, US Kent Lai - Salt Lake City UT, US Manshu Tang - Salt Lake City UT, US Douglas S. Auld - Beverly MA, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT The United States of American, as Represented by the Decretary, Department of Health and Human - Bethesda MD
Disclosed are inhibitors of human galactokinase of formula (1) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I)